HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company dedicated to developing multifunctional therapies for chronic liver and metabolic diseases, is presenting post-hoc analyses from two Phase 2 clinical studies of its lead candidate, berberine ursodeoxycholate (HTD1801), at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting. The event is being held from September 10-13, 2024, in Madrid, Spain.

HTD1801 is a gut-liver anti-inflammatory metabolic modulator being evaluated for its efficacy in patients with type 2 diabetes mellitus (T2DM). The data presented at EASD provides additional insights into HTD1801's potential to offer a novel, multifunctional treatment option for individuals managing T2DM.

“These data provide additional insight into the potential benefits of HTD1801, a novel, multifunctional therapy being developed for the treatment of patients with T2DM,” said Dr. Leigh MacConell, Chief Development Officer at HighTide Therapeutics. “We are excited about the progress of the two ongoing Phase 3 studies (NCT06350890, NCT06415773), which were fully enrolled in the second quarter of 2024. These studies will evaluate the efficacy and safety of HTD1801 in T2DM patients, either as monotherapy or in combination with metformin. We look forward to sharing the results, expected in 2025.”

The presentation titled “Efficacy of Berberine Ursodeoxycholate (HTD1801) in Chinese and Western Patients with T2DM” highlights the findings from the Phase 2 studies, shedding light on the consistency of HTD1801’s effects across diverse patient populations.